CN109475554A - 基于脂核苷酸的ards治疗 - Google Patents

基于脂核苷酸的ards治疗 Download PDF

Info

Publication number
CN109475554A
CN109475554A CN201780039385.4A CN201780039385A CN109475554A CN 109475554 A CN109475554 A CN 109475554A CN 201780039385 A CN201780039385 A CN 201780039385A CN 109475554 A CN109475554 A CN 109475554A
Authority
CN
China
Prior art keywords
cdp
composition
choline
ards
dag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780039385.4A
Other languages
English (en)
Chinese (zh)
Inventor
伊恩·克里斯托弗·戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CN109475554A publication Critical patent/CN109475554A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780039385.4A 2016-06-27 2017-06-27 基于脂核苷酸的ards治疗 Pending CN109475554A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355096P 2016-06-27 2016-06-27
US62/355,096 2016-06-27
PCT/US2017/039545 WO2018005527A1 (en) 2016-06-27 2017-06-27 Liponucleotide-based therapy for ards

Publications (1)

Publication Number Publication Date
CN109475554A true CN109475554A (zh) 2019-03-15

Family

ID=60786443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780039385.4A Pending CN109475554A (zh) 2016-06-27 2017-06-27 基于脂核苷酸的ards治疗

Country Status (9)

Country Link
US (2) US10874684B2 (enExample)
EP (2) EP4292651A3 (enExample)
JP (1) JP2019518798A (enExample)
KR (1) KR20190022682A (enExample)
CN (1) CN109475554A (enExample)
AU (1) AU2017289278A1 (enExample)
CA (1) CA3029005A1 (enExample)
SG (1) SG11201811595SA (enExample)
WO (1) WO2018005527A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475554A (zh) * 2016-06-27 2019-03-15 俄亥俄州国家创新基金会 基于脂核苷酸的ards治疗
WO2019005898A1 (en) 2017-06-27 2019-01-03 Ohio State Innovation Foundation LIPONUCLEOTID THERAPY FOR COPD
EP4125857A4 (en) * 2020-03-31 2024-04-17 Diffusion Pharmaceuticals LLC USE OF DIFFUSION ENHANCEMENT COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASE INDUCED BY VIRUSES AND BACTERIA
US12440464B2 (en) 2020-05-01 2025-10-14 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
WO2023173043A1 (en) * 2022-03-11 2023-09-14 Arizona Board Of Regents On Behalf Of Arizona State University Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection
WO2023177995A2 (en) * 2022-03-18 2023-09-21 Ohio State Innovation Foundation Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
US20040063674A1 (en) * 2001-07-13 2004-04-01 Levy Stuart B. Tetracycline compounds having target therapeutic activities
CN101066276A (zh) * 1994-07-01 2007-11-07 威尔斯塔特医疗公司 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
CN100469784C (zh) * 2001-11-21 2009-03-18 奥尔胡斯大学 甘油一酯和甘油二酯糖苷作为抗炎药物的用途
CN101506218A (zh) * 2005-05-23 2009-08-12 麻省理工学院 含有多不饱和脂肪酸的组合物及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883374T2 (de) * 1987-10-28 1993-12-09 Pro Neuron Inc Acylatiertes uridin und cytidin und deren verwendungen.
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
US20040049022A1 (en) * 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
MX2007005975A (es) * 2004-11-17 2007-10-08 Yissum Res Dev Co Uso de conjugados de lipido en el tratamiento de enfermedades.
CA2645647C (en) * 2005-05-23 2016-07-12 Massachusetts Institute Of Technology Compositions containing pufa and/or uridine and methods of use thereof
CN109475554A (zh) * 2016-06-27 2019-03-15 俄亥俄州国家创新基金会 基于脂核苷酸的ards治疗
EP3645010A4 (en) * 2017-06-27 2021-03-24 Ohio State Innovation Foundation NUCLEOTIDE-BASED THERAPY FOR ASTHMA
WO2019005898A1 (en) * 2017-06-27 2019-01-03 Ohio State Innovation Foundation LIPONUCLEOTID THERAPY FOR COPD

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
CN101066276A (zh) * 1994-07-01 2007-11-07 威尔斯塔特医疗公司 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
US20040063674A1 (en) * 2001-07-13 2004-04-01 Levy Stuart B. Tetracycline compounds having target therapeutic activities
CN100469784C (zh) * 2001-11-21 2009-03-18 奥尔胡斯大学 甘油一酯和甘油二酯糖苷作为抗炎药物的用途
CN101506218A (zh) * 2005-05-23 2009-08-12 麻省理工学院 含有多不饱和脂肪酸的组合物及其使用方法

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ERIC D LUND 等: "Phospholipid biosynthesis in the oyster protozoan parasite, Perkinsus marinus", 《MOL BIOCHEM PARASITOL》 *
H BRACHWITZ 等: "Synthesis and antiproliferative activity of cytidine-5"-alkylphosphonophosphates and structurally related compounds", 《CHEM PHYS LIPIDS》 *
HORROCKS, LLOYD A.; DORMAN, ROBERT V.: "Prevention by CDPcholine and CDPethanolamine of lipid changes during brain ischemia", 《NOVEL BIOCHEM., PHARMACOL. CLIN. ASPECTS CYTIDINEDIPHOSPHOCHOLINE, PROC.INT. MEET》 *
NAKAMURA, YUKI 等: "Diurnal and circadian expression profiles of glycerolipid biosynthetic", 《PLANT SIGNAL BEHAV》 *
SOMDUTTA SINHA ROY 等: "Inhibition of cholinephosphotransferase activity in lung injury induced by 2-chloroethyl ethyl sulfide, a mustard analog", 《J BIOCHEM MOL TOXICOL》 *
YU-FANG CHANG 等: "CTP synthetase and its role in phospholipid synthesis in the yeast Saccharomyces cerevisiae", 《PROG LIPID RES》 *
宋庆梅: "《生物化学》", 31 January 2015, 科学技术文献出版社 *
李辉: "《现代胸外科急症学》", 31 March 2006, 人民军医出版社 *
汤其群: "《生物化学与分子生物学》", 30 September 2015, 复旦大学出版社 *
葛宝丰 等: "《现代创伤治疗学》", 31 March 2001, 人民军医出版社 *
黄从新 等: "《现代心肺脑复苏学》", 30 November 1997, 人民卫生出版社 *

Also Published As

Publication number Publication date
US10874684B2 (en) 2020-12-29
EP4292651A2 (en) 2023-12-20
AU2017289278A1 (en) 2019-01-17
WO2018005527A1 (en) 2018-01-04
EP3474853A4 (en) 2020-02-19
EP4292651A3 (en) 2024-03-13
EP3474853A1 (en) 2019-05-01
KR20190022682A (ko) 2019-03-06
US20190134074A1 (en) 2019-05-09
CA3029005A1 (en) 2018-01-04
US20210069225A1 (en) 2021-03-11
SG11201811595SA (en) 2019-01-30
JP2019518798A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
CN109475554A (zh) 基于脂核苷酸的ards治疗
Futier et al. Lung-protective ventilation in abdominal surgery
CN101330912A (zh) 一种多西他赛的药用组合物、制备方法及用途
CN103083239A (zh) 一种蟾毒灵脂质体及其制备方法和应用
KR20190035776A (ko) 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
KR20200101960A (ko) 암치료약
US10828271B2 (en) Method for treating pleuroperitoneal membrane cancers by locally injecting disulfiram preparation
JP6462147B2 (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
CN116726021A (zh) 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途
CN111346081A (zh) 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
CN114522158A (zh) 用于制备治疗肝癌药物的代谢物及其应用
CN103417554B (zh) 一种抗肿瘤的药物组合物及其应用
CN114939122B (zh) 天然植物来源的联合抗肿瘤药物组合物
Athanasiadou et al. Successful treatment of rhinoorbital mucormycosis due to Rhizopus arrhizus with liposomal amphotericin B, posaconazole and surgical debridement in a child with neuroblastoma
Janssens et al. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2–4 laryngeal cancer: results of a phase III randomized trial
US11167002B2 (en) Pharmaceutical composition for the treatment of malignant neoplasms including sarcoma, cancers of liver, lung, bladder, blood and cervical, treatment of infectious diseases and type 2 diabetes
US10646553B2 (en) Use of recombinant human calcineurin B subunit
Trofimova et al. Medicinal Peptide Drugs: A Promising Direction in Modern Pharmacology
HK40003888A (en) Liponucleotide-based therapy for ards
TWI783175B (zh) 口服藥物組成物及其用途
WO2019164010A1 (ja) 膀胱がん用抗腫瘍剤および膀胱がんの処置方法
JP2020536092A (ja) 細菌感染症の治療方法
CN110891574A (zh) 用于预防和/或治疗肝细胞癌的美格列明
RU2519140C1 (ru) Способ лечения больных хроническими формами туберкулеза легких

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003888

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190315

WD01 Invention patent application deemed withdrawn after publication